Company
Mindset Pharma Inc
CNSX:MSET
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
65 stories
Mindset Pharma and PharmAla Biotech forge exclusive sales agreement
The company said that PharmAla will be the exclusive global reseller of Mindset’s pharmaceutical-grade psilocybin to licensed clinical researchers
Mindset Pharma presents data showing its psilocin prodrug is better tolerated than psilocybin
MSP-1014, Mindet’s prodrug, was shown in mouse and rat pharmacokinetics studies to be rapidly and completely metabolized to psilocin, particularly when taken orally
Mindset Pharma chooses pair of psychedelic drug candidates to move Family 2 program forward
“Our teams continue to advance our collaboration to bring this innovative therapeutic into first-in-human clinical development," said CEO James Lanthier
Mindset Pharma provides strategic intellectual property license to Cybin for preclinical psychedelic drug research
"Both our companies share the same ultimate goal of discovering and developing superior new psychedelic treatments to better meet the needs of patients," said Mindset CEO James Lanthier
Mindset Pharma to advance lead psychedelic drug candidate MSP-1014 into Phase 1 first-in-human trial
“Moving our lead drug candidate forward to human trials will contribute to Mindset’s goal of reaching patients suffering from mental health conditions who are waiting for new medicines with meaningful benefits," CEO James Lanthier said
Mindset Pharma files 16 national patent applications to protect family of novel next-generation psychedelics
The company's CEO James Lanthier said the filing of multiple international applications for Family 1 will offer protection for Mindset's drug candidates as it looked to move MSP-1014 into human clinical trials as early as 2023
Mindset Pharma expands IP portfolio with three non-tryptamine families of next-gen psychedelic compounds
The Canadian company said it is increasing its discovery pipeline with three additional “chemically distinct families of highly novel,” non-tryptamine drug candidate compounds
Mindset Pharma CEO spotlights firm’s intranasal formulation technology, robust IP portfolio and partnerships
“The initial Proof-of-Concept of our intranasal technology using 5-MeO-DMT showed promising results,” noted Mindset Pharma CEO James Lanthier
Mindset Pharma granted allowance for patent covering its short-duration novel psychedelic medications
"This notice of allowance reaffirms the strength of Mindset's IP position and facilitates our ongoing development of Family 2, a highly differentiated asset in our mission to help patients with unmet needs via the discovery of optimized psy
Mindset Pharma develops new patent-pending technology to deliver next generation psychedelic medicines intranasally
The new platform leverages the company's unique platform technology, altering the pharmacokinetics profile of the active pharmaceutical ingredient and can deliver improved central nervous system (CNS) penetration of the medicines, the compa
Mindset Pharma partners with the Centre for Addiction and Mental Health for study comparing its novel compound MSP-1014 with psilocybin
Mindset Pharma CEO James Lanthier said the collaboration would profile and build the company’s understanding of the observed superiority of its lead asset MSP-1014 to psilocybin at the molecular level
Mindset Pharma receives Notice of Allowance for psilocin derivatives patent application for treating central nervous system disorders
“This is a key step towards continued growth for Mindset and our developing pipeline of drug candidates,” Mindset Pharma CEO James Lanthier said
Mindset Pharma progresses plans for clinical trials of its advanced pre-clinical psychedelic MSP-1014
“We have selected an expert contract research organization, Clerkenwell Health, to lead the initial scientific discussions with the regulators in the UK as we start to pull together our clinical plans,” said Mindset CEO James Lanthier
Mindset Pharma strengthens IP portfolio with new provisional patent application
"As we get more human clinical data from first-generation psychedelic drugs, we will unravel how different patients respond to different psychedelic therapies,” the company’s CEO James Lanthier said
Mindset Pharma CEO James Lanthier says company pursuing development partners to support clinical process
In preclinical studies, Mindset's lead drug candidate MSP-1014, believed to be suited to address treatment-resistant depression and end-of-life cancer angst has showed improved efficacy and safety profile compared to first-generation psiloc
Mindset Pharma identifies new pharmacological insights of first-generation psychedelics through its COPE program with InterVivo Solutions
Specifically, Mindset has further developed standard pharmacokinetics and drug discrimination data and protocols across LSD, psilocybin, 5-MeO-DMT, and now psilocin
Mindset Pharma appoints Dr Fiona Randall as senior vice president of external alliance and scientific strategy
Randall is a renowned scientist with industry research experience with Eisai, GSK, and Merck and has worked in the USA, UK, China, and Japan
Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds, shows potential as substitute for microdosing
To better understand potential pro-cognitive benefits across a range of sub-hallucinogenic doses, Mindset will initiate a series of in vivo proof of concept studies, which will measure motivation and attention
Archive
NA Proactive news snapshot: Burcon NutraScience, Predictive Oncology, Red Pine Exploration, Silverton Metals UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mindset Pharma enters manufacturing deal with leading CDMO for next-generation psilocybin drug candidate, MSP-1014
The company said it continues to receive interest from potential partners for its wider portfolio of differentiated next-generation drug candidates
Stifel GMP encouraged by US$5M investment into Mindset Pharma, which provides "further validation for psychedelic sector"
As reported by Mindset, the tie-up consists of a US$5 million upfront cash payment and operational support to develop two 2nd generation psychedelic families in Mindset's pipeline through phase 1a and phase 1b trials
Mindset Pharma partners with McQuade Center for Strategic Research and Development to develop psychedelic medicine
MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, the company said
Mindset Pharma recaps 2021 milestones as it expands portfolio of next-generation psychedelic compounds
As the company enters 2022, it is progressing with investigational new drug-enabling studies for its lead candidate MSP-1014
NA Proactive news snapshot: Railtown AI Technologies, Altaley Mining, Mindset Pharma, FansUnite Entertainment ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mindset Pharma files international patent application covering its Family 3 psychedelic compounds
Chief Scientific Officer Joseph Araujo said 'such compounds may be optimal for indications in which a long-term, micro-dosing, paradigm is advantageous, such as ADHD or Alzheimer’s disease'
Mindset Pharma is pursuing breakthroughs in the psychedelics field with the help of “hard science”
The company saw early on that there would be a wave of interest in using psychedelic drugs as medication, but that ultimately there would be even more interest in next-generation drugs delivering greater benefits as medication with full pat
Psychedelic companies say Compass study result validates industry's hope to find alternative treatments for mental health
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues
Mindset Pharma announces poster presentation on lead candidate at Society for Neuroscience meeting
In focus will be the pre-clinical benchmarking data for Mindset's optimized psilocybin analog MSP-1014 compared to first-generation psychedelic compounds
HC Wainright & Co starts coverage on Mindset Pharma with a Buy rating and C$5 price target
The research group wrote that Toronto-based Mindset is “pioneering the next generation of psychedelic-enhanced therapies"
Mindset Pharma leading the charge to advance psychedelic medicines to treat mental illness
The company is developing intellectual property in two areas it believes are going to be the most valuable, namely, next-generation drugs and processes that can produce them at the lowest possible cost
Mindset Pharma ends its first full fiscal year with $6.6M in cash to advance novel psychedelic portfolio
CEO James Lanthier told investors that the firm has made “tremendous progress” advancing its library of next-generation psychedelic compounds
Mindset Pharma says it has expanded benchmark data for psychedelics under COPE program with InterVivo Solutions
The Toronto-based psychedelic company said that its benchmark data was determined by establishing standard pharmacokinetic (PK), brain penetration, and drug discrimination data and protocols for LSD, psilocybin, and 5-MeO-DMT
Mindset Pharma identifies additional next-generation 5-MeO-DMT-inspired lead candidates
The company says its Family 4 compounds MSP-4019 and MSP-4020 offer a broad range of pharmacological diversity suitable for in-clinic settings
Mindset Pharma added to NYSE-listed AdvisorShares Psychedelics ETF
The ETF is an actively managed product that invests in the flourishing psychedelic drugs industry
Mindset Pharma says further preclinical results for its MSP-4018 drug candidate demonstrate strong efficacy and improved safety profile
Due to the strong preclinical efficacy and safety data in support of MSP-4018, combined with its expedited manufacturing process, it believes its Family 4 clinical candidate has the potential to provide a safer and more scalable therapeutic
Mindset Pharma further validates lead candidate MSP-1014 as a next generation psilocybin analog through drug discrimination assay
Mindset Chief Scientific Officer Joseph Araujo said the results "further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate"
Maxim Group hikes price target for Mindset Pharma to US$1.50 after the company develops a specialized preclinical rodent model
Maxim's analysts said: "Mindset is making progress across its families of next-gen psychedelic compounds, demonstrating improved pharmacological and safety profiles across preclinical studies"
Mindset Pharma selects Treatment-Resistant Depression and End of Life Cancer Angst as initial target indications for MSP-1014
MSP-1014 is a novel patent-pending drug candidate that shows potential to be a safer second-generation psilocybin-like therapy with a decreased potential for side effects
Mindset Pharma develops specialized preclinical rodent trained studies with its drugs to differentiate between psychedelic and non-psychedelic effects
The drug discovery and development company said the studies will to enable it "to confirm the psychedelic effect of its novel compounds with greater accuracy"
Mindset Pharma reports encouraging safety data concerning its Family 4 group of DMT analogs
Head-to-head preclinical comparisons indicated the novel DMT/5-MeO-DMT-inspired analogs showed a significant decrease in serotonergic toxicity, which can cause a range of mild to life-threatening symptoms
NA Proactive news snapshot: Australis Capital, Mountain Valley MD, Kwesst Micro Systems, Todos Medical UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mindset Pharma says its Family 3 psilocybin analogs demonstrate long-acting duration in preclinical trials
The results have meaningful implications for psychedelic-based therapy at low doses, Mindset’s CEO James Lanthier said
Archive
NA Proactive news snapshot: Canada Silver Cobalt Works, FSD Pharma, Mydecine Innovations, Adyton Resources UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mindset Pharma files new US patent applications covering its Family 4 novel DMT compounds
The application covers a range of next generation drug candidates, as well as their related chemical process synthesis, composition of matter and therapeutic uses
Mindset Pharma advances psychedelic drug candidates' development as its patent applications are published
The three patent applications cover a range of the firm's so-called Family 1 and Family 2 compounds
Mindset Pharma reveals new results indicating its psychedelic analogs have greater efficacy and shorter durations compared with reference drugs
Results from its preclinical studies on its Family 2 group of novel psilocybin/psilocin analogs and its Family 4 novel DMT/ 5-MeO-DMT analogs demonstrated superior efficacy, safety and shorter duration of action
Mindset Pharma files international patent application covering its novel psilocybin synthesis process
The psychedelic drug company is pioneering a unique method to synthesize psilocybin and psilocin in a faster and more effective manner
Mindset Pharma is part of an exciting crop of psychedelics firms that are pushing next-generation opportunities
Investors are getting excited about next generation psychedelics that aim to deliver better benefits as medications for big population groups, with full patent protection
Mindset Pharma appoints Dr Ishrat Husain to its scientific advisory board
Dr. Husain will provide strategic guidance as the company develops a regulatory pathway for its novel psychedelic-based therapeutics to receive US FDA approval for patients suffering from mental illness
Mindset Pharma says new study data indicates MSP-1014 is safer and more effective than generic psilocybin in treating neuropsychiatric disorders
MSP-1014 demonstrated “superior efficacy” and an improved safety profile compared to generic psilocybin in a head-to-head clinical trial
Maxim Group initiates coverage of Mindset Pharma with a 'Buy' rating and price target of US$1
The analyst noted the company is building out next-generation psychedelics with four families of compounds including psilocybin and DMT/5-MeO-DMT analogues as well as a fifth family platform technology for improving psychedelic drugs
Archive
NA Proactive news snapshot: Infield Minerals, PlantX Life, Avalon GloboCare, Planet 13 Holdings, Vicinity Motor UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mindset Pharma says InterVivo releases first data set for jointly developed Cooperative Psychedelics Evaluation Platform program
The program aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT
Mindset Pharma selects next-generation psychedelic compound MSP-1014 as its lead clinical candidate
The differentiated psilocybin-based compound will move forward into current GMP-compliant manufacturing and IND-enabling studies